CoChat

The Importance of Steroid Uptake and Intracrine Action in Endometrial and Ovarian Cancers

Open access
Rižner, Tea Lanišnik, Thalhammer, Theresia, Özvegy-Laczka, Csilla · 2017 · Frontiers in Pharmacology
Cited by 40

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Endometrial and ovarian cancers predominately affect women after menopause, and are more frequently observed in developed countries. These are considered to be hormone-dependent cancers, as steroid hormones, and estrogens in particular, have roles in their onset and progression. After the production of estrogens in the ovary has ceased, estrogen synthesis occurs in peripheral tissues. This depends on the cellular uptake of estrone-sulfate and dehydroepiandrosterone-sulfate, as the most important steroid precursors in the plasma of postmenopausal women. The uptake through transporter proteins, such as those of the organic anion-transporting polypeptide (OATP) and organic anion-transporter (OAT) families, is followed by the synthesis and action of estradiol E2. Here, we provide an overview of the current understanding of this intracrine action of steroid hormones, which depends on the availability of the steroid precursors and transmembrane transporters for precursor uptake, along with the enzymes for the synthesis of E2. The data is also provided relating to the selected transmembrane transporters from the OATP, OAT, SLC51, and ABC-transporter families, and the enzymes involved in the E2-generating pathways in cancers of the endometrium and ovary. Finally, we discuss these transporters and enzymes as potential drug targets.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2017.00346

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 171

  1. Akhmedkhanov, 2001, Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives, Ann. N. Y. Acad. Sci., 943, 296, 10.1111/j.1749-6632.2001.tb03811.x · DOI · Paper page
  2. Al Sarakbi, 2006, The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer, Anticancer Res, 26, 4985
  3. Amant, 2005, Endometrial cancer, Lancet, 366, 491, 10.1016/S0140-6736(05)67063-8 · DOI · Paper page
  4. Anderson, 2003, Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial, JAMA, 290, 1739, 10.1001/jama.290.13.1739 · DOI · Paper page
  5. Arlanov, 2016, Functional characterization of common protein variants in the efflux transporter ABCC11 and identification of T546M as functionally damaging variant, Pharmacogenomics J, 16, 193, 10.1038/tpj.2015.27 · DOI
  6. Audet-Walsh, 2011, Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics, J. Clin. Endocrinol. Metab, 96, E330, 10.1210/jc.2010-2050 · DOI · Paper page
  7. Auner, 2010, ABC transporter gene expression in benign and malignant ovarian tissue, Gynecol. Oncol., 117, 198, 10.1016/j.ygyno.2009.10.077 · DOI
  8. Bagnoli, 2013, Clinicopathological impact of ABCC1/MRP1 and ABCC4/MRP4 in epithelial ovarian carcinoma, Biomed. Res. Int., 2013, 143202, 10.1155/2013/143202 · DOI
  9. Bai, 2000, Estrogen stimulation of ovarian surface epithelial cell proliferation, In Vitro Cell. Dev. Biol. Anim, 36, 657, 10.1290/1071-2690(2000)036<0657:ESOOSE>2.0.CO;2 · doi:10.1290/1071-2690(2000)036<0657:esoose>2.0.co;2
  10. Ballatori, 2005, OSTalpha-OSTbeta: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia, Hepatology, 42, 1270, 10.1002/hep.20961 · DOI · Paper page
  11. Ballatori, 2013, The heteromeric organic solute transporter, OSTalpha-OSTbeta/SLC51: a transporter for steroid-derived molecules, Mol. Aspects Med, 34, 683, 10.1016/j.mam.2012.11.005 · DOI · Paper page
  12. Ballatori, 2008, Ostalpha-Ostbeta is required for bile acid and conjugated steroid disposition in the intestine, kidney, and liver, Am. J. Physiol. Gastrointest Liver Physiol, 295, G179, 10.1152/ajpgi.90319.2008 · DOI · Paper page
  13. Bast, 2011, Molecular approaches to personalizing management of ovarian cancer, Ann. Oncol, 22, viii5, 10.1093/annonc/mdr516 · DOI
  14. Beral, 2007, Ovarian cancer and hormone replacement therapy in the Million Women Study, Lancet, 369, 1703, 10.1016/S0140-6736(07)60534-0 · DOI · Paper page
  15. Beral, 2015, Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies, Lancet, 385, 1835, 10.1016/S0140-6736(14)61687-1 · DOI · Paper page
  16. Binder, 2015, Molecular staging of gynecological cancer: what is the future?, Best Pract. Res. Clin. Obstet. Gynaecol, 29, 776, 10.1016/j.bpobgyn.2015.01.008 · DOI
  17. Blouin, 2009, Androgen metabolism in adipose tissue: recent advances, Mol. Cell. Endocrinol, 301, 97, 10.1016/j.mce.2008.10.035 · DOI
  18. Bodo, 2003, The role of multidrug transporters in drug availability, metabolism and toxicity, Toxicol. Lett, 141, 133, 10.1016/S0378-4274(02)00497-6 · DOI · Paper page
  19. Bogliolo, 2017, The role of fulvestrant in endometrial cancer, Expert Opin. Drug Metab. Toxicol, 13, 537, 10.1080/17425255.2016.1244264 · DOI
  20. Bogliolo, 2016, Effectiveness of aromatase inhibitors in the treatment of advanced endometrial adenocarcinoma, Arch. Gynecol. Obstet, 293, 701, 10.1007/s00404-015-3974-9 · DOI
  21. Bortfeld, 2006, Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system, Neuroscience, 137, 1247, 10.1016/j.neuroscience.2005.10.025 · DOI
  22. Brozic, 2008, Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1, Curr. Med. Chem, 15, 137, 10.2174/092986708783330629 · DOI · Paper page
  23. Burckhardt, 2011, In vitro and in vivo evidence of the importance of organic anion transporters (OATs) in drug therapy, Handb. Exp. Pharmacol, 201, 29, 10.1007/978-3-642-14541-4_2 · DOI · Paper page
  24. Caron, 2009, Profiling endogenous serum estrogen and estrogen-glucuronides by liquid chromatography-tandem mass spectrometry, Anal. Chem, 81, 10143, 10.1021/ac9019126 · DOI
  25. Cerami, 2012, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov, 2, 401, 10.1158/2159-8290.CD-12-0095 · DOI · Paper page
  26. Chaudhry, 2009, Resistance to chemotherapy and hormone therapy in endometrial cancer, Endocr. Relat. Cancer, 16, 363, 10.1677/ERC-08-0266 · DOI
  27. Chay, 2010, ER-60 (PDIA3) is highly expressed in a newly established serous ovarian cancer cell line, YDOV-139, Int. J. Oncol, 37, 399, 10.3892/ijo_00000688 · DOI
  28. Chen, 2016, Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade, Cancer Lett, 370, 153, 10.1016/j.canlet.2015.10.010 · DOI · Paper page
  29. Chene, 2014, Morphological and immunohistochemical study of ovarian and tubal dysplasia associated with tamoxifen, Eur. J. Histochem, 58, 2251, 10.4081/ejh.2014.2251 · DOI
  30. Cho, 2009, Molecular characterization of a new ovarian cancer cell line, YDOV-151, established from mucinous cystadenocarcinoma, Tohoku J. Exp. Med, 218, 129, 10.1620/tjem.218.129 · DOI
  31. Chura, Estrone sulfatase activity in patients with advanced ovarian cancer, Gynecol. Oncol, 112, 205, 10.1016/j.ygyno.2008.08.037 · DOI
  32. Chura, Steroid-converting enzymes in human ovarian carcinomas, Mol. Cell. Endocrinol, 301, 51, 10.1016/j.mce.2008.07.015 · DOI
  33. Clendenen, 2016, Premenopausal circulating androgens and risk of endometrial cancer: results of a prospective study, Horm. Cancer, 7, 178, 10.1007/s12672-016-0258-1 · DOI
  34. Cole, 2014, Multidrug resistance protein 1 (MRP1, ABCC1), a “multitasking” ATP-binding cassette (ABC) transporter, J. Biol. Chem, 289, 30880, 10.1074/jbc.R114.609248 · DOI · Paper page
  35. Conrad, 2002, A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance, Pharmacogenetics, 12, 321, 10.1097/00008571-200206000-00008 · DOI
  36. Cornel, 2017, High mRNA levels of 17beta-hydroxysteroid dehydrogenase type 1 correlate with poor prognosis in endometrial cancer, Mol. Cell. Endocrinol., 442, 51, 10.1016/j.mce.2016.11.030 · DOI · Paper page
  37. Cornel, 2012, Overexpression of 17β-hydroxysteroid dehydrogenase type 1 increases the exposure of endometrial cancer to 17β-estradiol, J. Clin. Endocrinol. Metab, 97, E591, 10.1210/jc.2011-2994 · DOI · Paper page
  38. Crawford, 2009, Circulating dehydroepiandrosterone sulfate concentrations during the menopausal transition, J. Clin. Endocrinol. Metab, 94, 2945, 10.1210/jc.2009-0386 · DOI
  39. Cui, 2001, Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6, J. Biol. Chem, 276, 9626, 10.1074/jbc.M004968200 · DOI · Paper page
  40. Daldorff, 2017, Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer, Br. J. Cancer, 116, 10, 10.1038/bjc.2016.405 · DOI
  41. Diep, 2015, Progesterone action in breast, uterine, and ovarian cancers, J. Mol. Endocrinol, 54, R31, 10.1530/JME-14-0252 · DOI · Paper page
  42. Domcke, 2013, Evaluating cell lines as tumour models by comparison of genomic profiles, Nat. Commun., 4, 2126, 10.1038/ncomms3126 · DOI · Paper page
  43. Ee, 2004, Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene, Cancer Res, 64, 1247, 10.1158/0008-5472.CAN-03-3583 · DOI · Paper page
  44. Ellis, 2015, Selective estrogen receptor modulators in clinical practice: a safety overview, Expert Opin. Drug Saf, 14, 921, 10.1517/14740338.2015.1014799 · DOI
  45. Elsnerova, 2016, Gene expression of membrane transporters: importance for prognosis and progression of ovarian carcinoma, Oncol. Rep, 35, 2159, 10.3892/or.2016.4599 · DOI
  46. Ferlay, 2013, GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No.11 (Internet)
  47. Fogle, 2007, Ovarian androgen production in postmenopausal women, J. Clin. Endocrinol. Metab, 92, 3040, 10.1210/jc.2007-0581 · DOI · Paper page
  48. Fournier, 2009, Estrogen formation in endometrial and cervix cancer cell lines: involvement of aromatase, steroid sulfatase and 17β-hydroxysteroid dehydrogenases (types 1, 5, 7 and 12), Mol. Cell. Endocrinol, 301, 142, 10.1016/j.mce.2008.08.027 · DOI
  49. Fuhrman, 2012, Estrogen metabolism and risk of breast cancer in postmenopausal women, J. Natl. Cancer Inst, 104, 326, 10.1093/jnci/djr531 · DOI · Paper page
  50. Furihata, 2015, Cancer-type organic anion transporting polypeptide 1B3: current knowledge of the gene structure, expression profile, functional implications and future perspectives, Curr. Drug Metab., 16, 474, 10.2174/1389200216666150812142715 · doi:10.2174/1389200216666150812142715
  51. Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci. Signal, 6, pl1, 10.1126/scisignal.2004088 · DOI · Paper page
  52. Giton, 2011, Serum sex steroids measured in middle-aged European and African-Caribbean men by gas chromatography-mass spectrometry, Eur. J. Endocrinol, 165, 917, 10.1530/EJE-11-0551 · DOI
  53. Gui, 2008, Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3, Eur. J. Pharmacol, 584, 57, 10.1016/j.ejphar.2008.01.042 · DOI · Paper page
  54. Hagenbuch, 2013, The SLCO (former SLC21) superfamily of transporters, Mol. Aspects Med, 34, 396, 10.1016/j.mam.2012.10.009 · DOI · Paper page
  55. Haley, 2016, Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease, Oncotarget, 7, 32810, 10.18632/oncotarget.9053 · DOI
  56. Hampel, 2011, The search for unaffected individuals with Lynch syndrome: do the ends justify the means?, Cancer Prev. Res., 4, 1, 10.1158/1940-6207.CAPR-10-0345 · DOI · Paper page
  57. Harrelson, 2016, Expanding the view of breast cancer metabolism: promising molecular targets and therapeutic opportunities, Pharmacol. Ther., 167, 60, 10.1016/j.pharmthera.2016.07.014 · DOI
  58. Hattori, 2016, Human C-terminally truncated ERα variants resulting from the use of alternative exons in the ligand-binding domain, Mol. Cell. Endocrinol., 425, 111, 10.1016/j.mce.2016.01.026 · DOI
  59. Hevir-Kene, 2015, The endometrial cancer cell lines Ishikawa and HEC-1A, and the control cell line HIEEC, differ in expression of estrogen biosynthetic and metabolic genes, and in androstenedione and estrone-sulfate metabolism, Chem. Biol. Interact., 234, 309, 10.1016/j.cbi.2014.11.015 · DOI
  60. Hewitt, 2016, What's new in estrogen receptor action in the female reproductive tract, J. Mol. Endocrinol, 56, R55, 10.1530/jme-15-0254 · DOI · Paper page
  61. Higuchi, 2016, Contribution of estrone sulfate to cell proliferation in aromatase inhibitor (AI) -resistant, hormone receptor-positive breast cancer, PLoS ONE, 11, e0155844, 10.1371/journal.pone.0155844 · DOI
  62. Ho, 2003, Estrogen, progesterone and epithelial ovarian cancer, Reprod. Biol. Endocrinol., 1, 73, 10.1186/1477-7827-1-73 · DOI · Paper page
  63. Hu, 2005, Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma, Int. J. Gynecol. Cancer, 15, 537, 10.1111/j.1525-1438.2005.15321.x · DOI
  64. Imai, 2003, Breast cancer resistance protein exports sulfated estrogens but not free estrogens, Mol. Pharmacol, 64, 610, 10.1124/mol.64.3.610 · DOI · Paper page
  65. Ishikawa, 2009, Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics, J. Exp. Ther. Oncol., 8, 5
  66. Jasonni, 1984, Estrone sulphate plasma levels in postmenopausal women with and without endometrial cancer, Cancer, 53, 2698, 10.1002/1097-0142(19840615)53:12<2698::AID-CNCR2820531223>3.0.CO;2-O · DOI
  67. Jenabi, 2015, The effect of body mass index on endometrial cancer: a meta-analysis, Public Health, 129, 872, 10.1016/j.puhe.2015.04.017 · DOI
  68. Jeon, 2016, Effect of steroid hormones, estrogen and progesterone, on epithelial mesenchymal transition in ovarian cancer development, J. Steroid Biochem. Mol. Biol., 158, 1, 10.1016/j.jsbmb.2016.02.005 · DOI
  69. Kalliokoski, 2009, Impact of OATP transporters on pharmacokinetics, Br. J. Pharmacol, 158, 693, 10.1111/j.1476-5381.2009.00430.x · DOI · Paper page
  70. Kandoth, 2013, Integrated genomic characterization of endometrial carcinoma, Nature, 497, 67, 10.1038/nature12113 · DOI · Paper page
  71. Keefe, 2014, Simultaneous measurement of thirteen steroid hormones in women with polycystic ovary syndrome and control women using liquid chromatography-tandem mass spectrometry, PLoS ONE, 9, e93805, 10.1371/journal.pone.0093805 · DOI · Paper page
  72. Key, 2002, Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies, J. Natl. Cancer Inst, 94, 606, 10.1093/jnci/94.8.606 · DOI · Paper page
  73. Kobayashi, 2005, Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]), J. Pharm. Pharmacol, 57, 573, 10.1211/0022357055966 · DOI · Paper page
  74. Koepsell, 2013, The SLC22 family with transporters of organic cations, anions and zwitterions, Mol. Aspects Med, 34, 413, 10.1016/j.mam.2012.10.010 · DOI · Paper page
  75. Kovacsics, 2016, The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions, Expert Opin. Drug Metab. Toxicol., 13, 409, 10.1080/17425255.2017.1253679 · DOI · Paper page
  76. Kreuzinger, 2015, Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer, Cancer Lett, 362, 218, 10.1016/j.canlet.2015.03.040 · DOI
  77. Kruh, 2007, ABCC10, ABCC11, and ABCC12, Pflugers Arch, 453, 675, 10.1007/s00424-006-0114-1 · DOI
  78. Kullak-Ublick, 1998, Dehydroepiandrosterone sulfate (DHEAS): identification of a carrier protein in human liver and brain, FEBS Lett, 424, 173, 10.1016/S0014-5793(98)00168-9 · DOI · Paper page
  79. Kullak-Ublick, 2001, Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver, Gastroenterology, 120, 525, 10.1053/gast.2001.21176 · DOI · Paper page
  80. Kunicka, 2014, Importance of ABCC1 for cancer therapy and prognosis, Drug Metab. Rev, 46, 325, 10.3109/03602532.2014.901348 · DOI
  81. Labrie, 2003, Extragonadal synthesis of sex steroids: intracrinology, Ann. Endocrinol., 64, 95
  82. Labrie, 2006, Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women, J. Steroid Biochem. Mol. Biol, 99, 182, 10.1016/j.jsbmb.2006.02.004 · DOI · Paper page
  83. Labrie, 2009, Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer, J. Steroid Biochem. Mol. Biol, 113, 52, 10.1016/j.jsbmb.2008.11.004 · DOI
  84. Labrie, 2015, Letter to the editor: superior mass spectrometry-based estrogen assays should replace immunoassays, J. Clin. Endocrinol. Metab., 100, L86, 10.1210/jc.2015-2930 · DOI
  85. Lancaster, 2013, Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics, Mol. Cancer Ther, 12, 1537, 10.1158/1535-7163.MCT-12-0926 · DOI
  86. Langdon, 2017, Endocrine therapy in epithelial ovarian cancer, Expert Rev. Anticancer Ther, 17, 109, 10.1080/14737140.2017.1272414 · DOI
  87. Lee, 2010, Genetic variation in the progesterone receptor gene and risk of endometrial cancer: a haplotype-based approach, Carcinogenesis, 31, 1392, 10.1093/carcin/bgq113 · DOI
  88. Lee, 2005, Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry, J. Biol. Chem, 280, 9610, 10.1074/jbc.M411092200 · DOI · Paper page
  89. Lee, 2005, Investigation of efflux transport of dehydroepiandrosterone sulfate and mitoxantrone at the mouse blood-brain barrier: a minor role of breast cancer resistance protein, J. Pharmacol. Exp. Ther, 312, 44, 10.1124/jpet.104.073320 · DOI
  90. Lépine, 2010, Circulating estrogens in endometrial cancer cases and their relationship with tissular expression of key estrogen biosynthesis and metabolic pathways, J. Clin. Endocrinol. Metab., 95, 2689, 10.1210/jc.2010-2648 · DOI · Paper page
  91. Levin, 2011, Minireview: extranuclear steroid receptors: roles in modulation of cell functions, Mol. Endocrinol, 25, 377, 10.1210/me.2010-0284 · DOI · Paper page
  92. Li, 2014, Role of solute carriers in response to anticancer drugs, Mol. Cell. Ther., 2, 15, 10.1186/2052-8426-2-15 · DOI
  93. Lukanova, 2004, Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women, Int. J. Cancer, 108, 425, 10.1002/ijc.11529 · DOI · Paper page
  94. Lurie, 2011, Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium, PLoS ONE, 6, e20703, 10.1371/journal.pone.0020703 · DOI
  95. Luu-The, 2010, The intracrine sex steroid biosynthesis pathways, Prog. Brain Res., 181, 177, 10.1016/S0079-6123(08)81010-2 · DOI
  96. Maeda, 2015, Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs, Biol. Pharm. Bull, 38, 155, 10.1248/bpb.b14-00767 · DOI
  97. Manna, 2016, Dysregulation of Aromatase in breast, endometrial, and ovarian cancers: an overview of therapeutic strategies, Prog. Mol. Biol. Transl. Sci., 144, 487, 10.1016/bs.pmbts.2016.10.002 · DOI
  98. Matsumoto, 2014, ABCC11/MRP8 expression in the gastrointestinal tract and a novel role for pepsinogen secretion, Acta Histochem. Cytochem, 47, 85, 10.1267/ahc.13040 · doi:10.1267/ahc.13040
  99. Mazumdar, 2009, Binary and ternary crystal structure analyses of a novel inhibitor with 17beta-HSD type 1: a lead compound for breast cancer therapy, Biochem. J, 424, 357, 10.1042/BJ20091020 · DOI
  100. Meyer zu Schwabedissen, 2008, Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer, Cancer Res, 68, 9338, 10.1158/0008-5472.CAN-08-0265 · DOI · Paper page
  101. Milewich, 1987, In situ steroid sulfatase activity in human epithelial carcinoma cells of vaginal, ovarian, and endometrial origin, J. Clin. Endocrinol. Metab, 65, 164, 10.1210/jcem-65-1-164 · DOI
  102. Modan, 1998, Cancer incidence in a cohort of infertile women, Am. J. Epidemiol, 147, 1038, 10.1093/oxfordjournals.aje.a009397 · DOI · Paper page
  103. Modugno, 2012, Hormone response in ovarian cancer: time to reconsider as a clinical target?, Endocr. Relat. Cancer, 19, R255, 10.1530/ERC-12-0175 · DOI
  104. Mueller, 2015, The regulation of steroid action by sulfation and desulfation, Endocr. Rev., 36, 526, 10.1210/er.2015-1036 · DOI · Paper page
  105. Murali, 2014, Classification of endometrial carcinoma: more than two types, Lancet Oncol, 15, e268, 10.1016/S1470-2045(13)70591-6 · DOI · Paper page
  106. Mylonas, 2010, Prognostic significance and clinical importance of estrogen receptor alpha and beta in human endometrioid adenocarcinomas, Oncol. Rep., 24, 385, 10.3892/or_00000871 · DOI
  107. Nakamura, 2010, Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer Hum, Pathol., 41, 1516, 10.1016/j.humpath.2010.05.006 · doi:10.1016/j.humpath.2010.05.006
  108. Nakamura, 2014, Molecular characterization of CD133+ cancer stem-like cells in endometrial cancer, Int. J. Oncol, 44, 669, 10.3892/ijo.2013.2230 · doi:10.3892/ijo.2013.2230
  109. Nozaki, 2007, Characterization of the uptake of organic anion transporter (OAT) 1 and OAT3 substrates by human kidney slices, J. Pharmacol. Exp. Ther, 321, 362, 10.1124/jpet.106.113076 · DOI
  110. Obaidat, 2012, The expression and function of organic anion transporting polypeptides in normal tissues and in cancer, Annu. Rev. Pharmacol. Toxicol., 52, 135, 10.1146/annurev-pharmtox-010510-100556 · DOI · Paper page
  111. Ogane, 2013, Prognostic value of organic anion transporting polypeptide 1B3 and copper transporter 1 expression in endometrial cancer patients treated with paclitaxel and carboplatin, Biomed. Res, 34, 143, 10.2220/biomedres.34.143 · DOI
  112. Okuda, 2001, Steroid sulfatase expression in ovarian clear cell adenocarcinoma: immunohistochemical study, Gynecol. Oncol., 82, 427, 10.1006/gyno.2001.6322 · DOI
  113. Pan, 2010, Endometrioid ovarian carcinoma benefits from aromatase inhibitors: case report and literature review, Curr. Oncol, 17, 82, 10.3747/co.v17i6.676 · doi:10.3747/co.v17i6.676
  114. Park, 2008, Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha, Mol. Endocrinol, 22, 2085, 10.1210/me.2007-0512 · DOI · Paper page
  115. Pathirage, 2006, Expression of aromatase, estrogen receptors, and their coactivators in patients with endometrial cancer, Fertil. Steril, 86, 469, 10.1016/j.fertnstert.2005.12.057 · DOI
  116. Pautier, 2012, A phase II multicentre randomized open-label study of oral steroid sulphatase (STS) inhibitor irosustat (BN83495) versus megestrol acetate (MA) in women with advanced/recurrent endometrial cancer, AnnalsOncol, 23, 329
  117. Pearce, 2008, Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis, Br. J. Cancer, 98, 282, 10.1038/sj.bjc.6604170 · DOI
  118. Pizzagalli, 2003, Identification of steroid sulfate transport processes in the human mammary gland, J. Clin. Endocrinol. Metab., 88, 3902, 10.1210/jc.2003-030174 · DOI · Paper page
  119. Potischman, 1996, Case-control study of endogenous steroid hormones and endometrial cancer, J. Natl. Cancer Inst, 88, 1127, 10.1093/jnci/88.16.1127 · DOI · Paper page
  120. Prat, 2015, Staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication of guidelines from the international Federation of Gynecology and Obstetrics (FIGO), Obstet. Gynecol, 126, 171, 10.1097/AOG.0000000000000917 · DOI · Paper page
  121. Prossnitz, 2008, Estrogen signaling through the transmembrane G protein-coupled receptor GPR30, Annu. Rev. Physiol., 70, 165, 10.1146/annurev.physiol.70.113006.100518 · DOI · Paper page
  122. Ramalingam, 2016, Morphologic, immunophenotypic, and molecular features of epithelial ovarian cancer, Oncology, 30, 166
  123. Ren, 2015, Local estrogen metabolism in epithelial ovarian cancer suggests novel targets for therapy, J. Steroid Biochem. Mol. Biol., 150, 54, 10.1016/j.jsbmb.2015.03.010 · DOI · Paper page
  124. Rižner, 2013, Estrogen biosynthesis, phase I and phase II metabolism, and action in endometrial cancer, Mol. Cell. Endocrinol, 381, 124, 10.1016/j.mce.2013.07.026 · DOI
  125. Rojas, 2016, Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment, Int. J. Mol. Sci., 17, 2113, 10.3390/ijms17122113 · DOI · Paper page
  126. Romero-Sánchez, 2008, Expression profile of heptahelical putative membrane progesterone receptors in epithelial ovarian tumors, Hum. Pathol, 39, 1026, 10.1016/j.humpath.2007.11.007 · DOI
  127. Roth, 2012, OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies, Br. J. Pharmacol, 165, 1260, 10.1111/j.1476-5381.2011.01724.x · DOI · Paper page
  128. Rutherford, 2000, Absence of estrogen receptor-β expression in metastatic ovarian cancer, Obstet. Gynecol., 96, 417, 10.1016/S0029-7844(00)00917-0 · doi:10.1016/s0029-7844(00)00917-0
  129. Ryan, 2005, Endometrial cancer, Cell Tissue Res, 322, 53, 10.1007/s00441-005-1109-5 · DOI
  130. Saegusa, 2000, Changes in expression of estrogen receptors alpha and beta in relation to progesterone receptor and pS2 status in normal and malignant endometrium, Jpn. J. Cancer Res, 91, 510, 10.1111/j.1349-7006.2000.tb00975.x · DOI · Paper page
  131. Sakaguchi, 2002, Expression of oestrogen receptor alpha and beta in uterine endometrial and ovarian cancers, Eur. J. Cancer, 38, S74, 10.1016/S0959-8049(02)00296-4 · DOI
  132. Samojlik, 1980, Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma, J. Clin. Invest, 65, 602, 10.1172/JCI109705 · DOI
  133. Sarkadi, 2006, Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system, Physiol. Rev, 86, 1179, 10.1152/physrev.00037.2005 · DOI · Paper page
  134. Scharl, 2016, Significance of ovarian function suppression in endocrine therapy for breast cancer in pre-menopausal women, Geburtshilfe Frauenheilkd, 76, 516, 10.1055/s-0042-106389 · DOI
  135. Schinkel, 2003, Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview, Adv. Drug Deliv. Rev, 55, 3, 10.1016/S0169-409X(02)00169-2 · DOI · Paper page
  136. Secky, 2013, The sulfatase pathway for estrogen formation: targets for the treatment and diagnosis of hormone-associated tumors, J. Drug Deliv., 2013, 957605, 10.1155/2013/957605 · DOI
  137. Setiawan, 2013, Type I and II endometrial cancers: have they different risk factors?, J. Clin. Oncol, 31, 2607, 10.1200/JCO.2012.48.2596 · DOI · Paper page
  138. Seward, 2003, Functional complementation between a novel mammalian polygenic transport complex and an evolutionarily ancient organic solute transporter, OSTalpha-OSTbeta, J. Biol. Chem, 278, 27473, 10.1074/jbc.M301106200 · DOI · Paper page
  139. Sharom, 2014, Complex interplay between the p-glycoprotein multidrug efflux pump and the membrane: its role in modulating protein function, Front. Oncol., 4, 41, 10.3389/fonc.2014.00041 · DOI · Paper page
  140. Simmen, 2008, The Krüppel-like factor 9 (KLF9) network in HEC-1-A endometrial carcinoma cells suggests the carcinogenic potential of dys-regulated KLF9 expression, Reprod. Biol. Endocrinol., 6, 41, 10.1186/1477-7827-6-41 · DOI
  141. Sinreih, 2013, Altered expression of genes involved in progesterone biosynthesis, metabolism and action in endometrial cancer, Chem. Biol. Interact, 202, 210, 10.1016/j.cbi.2012.11.012 · DOI
  142. Slot, 2011, Mammalian multidrug-resistance proteins (MRPs), Essays Biochem, 50, 179, 10.1042/bse0500179 · DOI · Paper page
  143. Smith, 2003, Aromatase inhibitors in breast cancer, N. Engl. J. Med, 348, 2431, 10.1056/NEJMra023246 · DOI · Paper page
  144. Smuc, 2009, Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer, Mol. Cell. Endocrinol, 301, 74, 10.1016/j.mce.2008.09.019 · DOI
  145. Smuc, 2006, Expression analysis of estrogen-metabolizing enzymes in human endometrial cancer, Mol. Cell. Endocrinol, 248, 114, 10.1016/j.mce.2005.10.013 · DOI
  146. Stanway, 2007, Steroid sulfatase: a new target for the endocrine therapy of breast cancer, Oncologist, 12, 370, 10.1634/theoncologist.12-4-370 · DOI · Paper page
  147. Stieger, 2014, Organic anion-transporting polypeptides, Curr. Top. Membr., 73, 205, 10.1016/B978-0-12-800223-0.00005-0 · DOI · Paper page
  148. Sugawara, 2004, Expression of enzyme associated with steroid hormone synthesis and local production of steroid hormone in endometrial carcinoma cells, J. Endocrinol, 180, 135, 10.1677/joe.0.1800135 · DOI
  149. Svoboda, 2011, Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport, Biomed. Pharmacother., 65, 417, 10.1016/j.biopha.2011.04.031 · DOI
  150. Szakacs, 2008, The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox), Drug Discov. Today, 13, 379, 10.1016/j.drudis.2007.12.010 · DOI · Paper page
  151. Tamai, 2000, Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family, Biochem. Biophys. Res. Commun, 273, 251, 10.1006/bbrc.2000.2922 · DOI · Paper page
  152. Tamai, 2001, Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C, Pharm. Res, 18, 1262, 10.1023/A:1013077609227 · DOI · Paper page
  153. Tashiro, 2014, High expression of organic anion transporter 2 and organic cation transporter 2 is an independent predictor of good outcomes in patients with metastatic colorectal cancer treated with FOLFOX-based chemotherapy, Am. J. Cancer Res, 4, 528
  154. Thakkar, 2015, Role of organic anion-transporting polypeptides (OATPs) in cancer therapy, AAPS J, 17, 535, 10.1208/s12248-015-9740-x · DOI
  155. Thomas, 2011, The different roles of ER subtypes in cancer biology and therapy, Nat. Rev. Cancer, 11, 597, 10.1038/nrc3093 · DOI · Paper page
  156. Thomas, 2015, Estrogen O-sulfamates and their analogues: clinical steroid sulfatase inhibitors with broad potential, J. Steroid Biochem. Mol. Biol., 153, 160, 10.1016/j.jsbmb.2015.03.012 · DOI
  157. Traboulsi, 2017, Antiestrogens: structure-activity relationships and use in breast cancer treatment, J. Mol. Endocrinol, 58, R15, 10.1530/JME-16-0024 · DOI
  158. Ugele, 2003, Characterization and identification of steroid sulfate transporters of human placenta, Am. J. Physiol. Endocrinol. Metab, 284, E390, 10.1152/ajpendo.00257.2002 · DOI · Paper page
  159. Wan, 2016, The levels of the sex hormones are not different between type 1 and type 2 endometrial cancer, Sci. Rep., 6, 39744, 10.1038/srep39744 · DOI
  160. Ween, 2015, The role of ABC transporters in ovarian cancer progression and chemoresistance, Crit. Rev. Oncol. Hematol, 96, 220, 10.1016/j.critrevonc.2015.05.012 · DOI · Paper page
  161. Wlcek, 2008, Altered expression of organic anion transporter polypeptide (OATP) genes in human breast carcinoma, Cancer Biol. Ther, 7, 1450, 10.4161/cbt.7.9.6282 · DOI
  162. Woo, 2010, Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template, J. Med. Chem, 53, 2155, 10.1021/jm901705h · DOI
  163. Yamaguchi, 2010, Transport of estrone 3-sulfate mediated by organic anion transporter OATP4C1: estrone 3-sulfate binds to the different recognition site for digoxin in OATP4C1, Drug Metab. Pharmacokinet., 25, 314, 10.2133/dmpk.25.314 · doi:10.2133/dmpk.25.314
  164. Yasui, 2012, Androgen in postmenopausal women, J. Med. Invest, 59, 12, 10.2152/jmi.59.12 · DOI
  165. Yeramian, 2013, Endometrial carcinoma: molecular alterations involved in tumor development and progression, Oncogene, 32, 403, 10.1038/onc.2012.76 · DOI · Paper page
  166. Zakharov, 2010, Suppressed expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma, Int. J. Clin. Exp. Pathol, 3, 608
  167. Zannoni, 2013, The expression ratios of estrogen receptor alpha (ERalpha) to estrogen receptor beta1 (ERbeta1) and ERalpha to ERbeta2 identify poor clinical outcome in endometrioid endometrial cancer, Hum. Pathol., 44, 1047, 10.1016/j.humpath.2012.09.007 · DOI
  168. Zelcer, 2003, Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4), Biochem. J, 371, 361, 10.1042/bj20021886 · DOI · Paper page
  169. Zhang, 2008, Identification and characterization of ovarian cancer-initiating cells from primary human tumors, Cancer Res, 68, 4311, 10.1158/0008-5472.CAN-08-0364 · DOI · Paper page
  170. Zhao, 2014, Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer, World J. Clin. Oncol, 5, 248, 10.5306/wjco.v5.i3.248 · DOI
  171. Zhou, 2014, Anti-tumor effect of Shu-Gan-Liang-Xue decoction in breast cancer is related to the inhibition of aromatase and steroid sulfatase expression, J. Ethnopharmacol, 154, 687, 10.1016/j.jep.2014.04.045 · DOI

Cited by

See all 40

Metadata

Authors
Rižner, T. L., Thalhammer, T., & Özvegy-Laczka, C.
Venue
Frontiers in Pharmacology
Published
2017-06-19
Volume
8
Pages
346-346
ISSN
1663-9812 (ISSN-L)
OpenAlex
W2625072044
Cited by
40
References
12
FWCI
2.95
Type
journal article
Language
en
Open access
gold
Funders
  • Javna Agencija za Raziskovalno Dejavnost RS (J3-5510)
  • Országos Tudományos Kutatási Alapprogramok (109423)
  • Magyar Tudományos Akadémia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.